Literature DB >> 1335792

Epstein-Barr virus and Burkitt's lymphoma.

I Magrath1, V Jain, K Bhatia.   

Abstract

Recent investigations indicate that Burkitt's lymphoma consists of several subtypes, defined by their clinical and molecular features. Each geographical region so far studied appears to consist of a different mixture of subtypes. Interestingly, there appear to be geographic 'gradients' with respect to the fraction of tumors associated with EBV and the type of 8;14 chromosomal translocation. The rate of EBV association is highest in Equatorial Africa, lowest in North America and intermediate in South America. The fraction of tumors with breakpoints far upstream of the c-myc gene follows a similar pattern. These findings strongly suggest that the subtypes of Burkitt's lymphoma are environmentally determined, and we propose that the pattern of infection (e.g. malaria) to which the young child is exposed influences the tumor subtype distribution by altering the relative and absolute numbers of various B cell precursors at sites of B cell ontogeny (the bone marrow, and possibly mesentery). These B cell precursors are the cells which are susceptible to the specific chromosomal translocations associated with Burkitt's lymphoma. We further propose that immunoglobulin enhancers (recognized and unrecognized) both influence the likelihood of the translocation occurring, and in at least a fraction of cases, contribute to the deregulation of a c-myc. EBV, via EBNA-1, the only invariably expressed latent-gene in Burkitt's lymphoma, probably influences c-myc expression in Burkitt's lymphoma by increasing immunoglobulin enhancer function. Thus, in effect, EBV collaborates with the translocations associated with Burkitt's lymphoma in causing c-myc deregulation. This collaboration is independent of the breakpoint location. While other molecular abnormalities must be able to contribute to myc deregulation in the same way, EBV association in Burkitt's lymphoma is probably determined by the age at which EBV infection occurs (being more likely when infection occurs in very young children) and perhaps also by other infectious diseases that numerically influence the fraction, and predominant stage of differentiation (and hence translocation breakpoint sites) of immature B cells infected by EBV. The presence of EBV in many such cells greatly increases the incidence rate of Burkitt's lymphoma, since one of the genetic lesions needed to deregulate c-myc is already present.

Entities:  

Mesh:

Year:  1992        PMID: 1335792

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  20 in total

Review 1.  Signaling activities of gammaherpesvirus membrane proteins.

Authors:  B Damania; J K Choi; J U Jung
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

Review 2.  Molecular diagnosis of Epstein-Barr virus-related diseases.

Authors:  M L Gulley
Journal:  J Mol Diagn       Date:  2001-02       Impact factor: 5.568

3.  MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.

Authors:  Martin S Staege; Steven P Lee; Teresa Frisan; Josef Mautner; Siegfried Scholz; Alexander Pajic; Alan B Rickinson; Maria G Masucci; Axel Polack; Georg W Bornkamm
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-26       Impact factor: 11.205

4.  Viral response to chemotherapy in endemic burkitt lymphoma.

Authors:  Weihua Tang; Paula Harmon; Margaret L Gulley; Charles Mwansambo; Peter N Kazembe; Francis Martinson; Clifford Wokocha; Shannon C Kenney; Irving Hoffman; Carlie Sigel; Susan Maygarden; Mariah Hoffman; Carol Shores
Journal:  Clin Cancer Res       Date:  2010-03-16       Impact factor: 12.531

5.  Functional differences between BHRF1, the Epstein-Barr virus-encoded Bcl-2 homologue, and Bcl-2 in human epithelial cells.

Authors:  C W Dawson; J Dawson; R Jones; K Ward; L S Young
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

Review 6.  A review on EBV encoded and EBV-induced host microRNAs expression profile in different lymphoma types.

Authors:  Saber Soltani; Armin Zakeri; Alireza Tabibzadeh; Amir Mohammad Zakeri; Milad Zandi; Saba Siavoshi; Saba Seifpour; Abbas Farahani
Journal:  Mol Biol Rep       Date:  2021-02-01       Impact factor: 2.316

7.  Cancer prevention: accomplishments and prospects.

Authors:  P Cole; Y Amoateng-Adjepong
Journal:  Am J Public Health       Date:  1994-01       Impact factor: 9.308

8.  Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt's lymphoma cells.

Authors:  Ana Carolina Dos Santos Ferreira; Renan Amphilophio Fernandes; Jolie Kiemlian Kwee; Claudete Esteves Klumb
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-01       Impact factor: 4.553

Review 9.  Gamma herpesviruses: pathogenesis of infection and cell signaling.

Authors:  J Rajcáni; M Kúdelová
Journal:  Folia Microbiol (Praha)       Date:  2003       Impact factor: 2.099

Review 10.  Mechanisms involved in Burkitt's tumor formation.

Authors:  M R Campanero
Journal:  Clin Transl Oncol       Date:  2008-05       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.